Skip to main content
. 2020 Mar 18;10(3):e034716. doi: 10.1136/bmjopen-2019-034716

Figure 6.

Figure 6

Sensitivity analyses: incremental costs per person over a lifetime for the Biomarker Testing strategy vs the No Testing strategy. GCK, glucokinase; HBGM, home blood glucose monitoring; HNF1/4A, hepatocyte nuclear factor 1/4 alpha; UCPCR, urinary C peptide to creatinine ratio.